F&S Pharmatech

About F&S Pharmatech

Nanjing F&S Pharmatech Co., Ltd. is a pharmaceutical company established in October 2015, focusing on the development and production of differentiated generic drugs. The company was co-founded by its core management team, Suzhou Crystal Pharmatech Co., Ltd., and the Bank of Nanjing. The chairman and CEO is Dr. Yuan Fang, a serial entrepreneur with a Ph.D. in chemistry from Nanjing University and postdoctoral experience at Stanford University. Co-founder and Executive Vice President, Lu Fusheng, holds a master's degree in Pharmaceutical Analysis from China Pharmaceutical University and a master's in International Drug Engineering Management from Peking University, contributing over 20 years of industry experience.

F&S Pharmatech operates an integrated business model that spans from research and development to the commercialization of active pharmaceutical ingredients (APIs) and advanced intermediates. The company's revenue is generated through the sale of these products and by providing contract manufacturing services to a global client base, which includes notable partners like Sanofi. It leverages China's Marketing Authorization Holder (MAH) system to industrialize its differentiated generic drugs, aiming to make essential medicines more accessible and affordable. The company has established a comprehensive R&D center and a 50-acre production facility, which includes a high-potency workshop and utilizes advanced technologies like hot melt extrusion (HME).

The company's product pipeline is concentrated on treatments for cardiovascular diseases, oncology, and endocrine disorders. F&S Pharmatech has successfully developed over 20 products, with several already approved for market. Key products include Yixintan® (Sacubitril/Valsartan Sodium Tablets) for hypertension and heart failure, and He Tang Jing® (Dapagliflozin Tablets) for diabetes, both of which broke patent barriers to achieve early market entry. The firm's strategy involves creating proprietary intellectual property solutions through in-house R&D and strategic collaborations, which allows it to produce differentiated and cost-effective medications. This approach has enabled the company to achieve significant milestones, including multiple rounds of financing and receiving numerous accolades such as being named a National High-Tech Enterprise and a potential unicorn enterprise in Jiangsu Province.